Cargando…

An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions

BACKGROUND: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone (“Z-drugs”) clinical concerns relating to their potential of abuse, dependence, and withdrawal have been reported over time. We aimed here at asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Schifano, Fabrizio, Chiappini, Stefania, Corkery, John M, Guirguis, Amira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441128/
https://www.ncbi.nlm.nih.gov/pubmed/30722037
http://dx.doi.org/10.1093/ijnp/pyz007
_version_ 1783407498207690752
author Schifano, Fabrizio
Chiappini, Stefania
Corkery, John M
Guirguis, Amira
author_facet Schifano, Fabrizio
Chiappini, Stefania
Corkery, John M
Guirguis, Amira
author_sort Schifano, Fabrizio
collection PubMed
description BACKGROUND: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone (“Z-drugs”) clinical concerns relating to their potential of abuse, dependence, and withdrawal have been reported over time. We aimed here at assessing these issues analyzing datasets of adverse drug reactions provided by the European Medicines Agency through the EudraVigilance system. METHODS: Analyzing the adverse drug reactions databases of each Z-drug, descriptive analyses have been performed on cases and proportional reporting ratios (PRRs) computed. RESULTS: An overall number of 33 240 (e.g., 23 420 zolpidem; 9283 zopiclone; and 537 zaleplon) misuse-, abuse-, dependence-, and withdrawal-related adverse drug reactions, corresponding to some 6246 unique patients given Z-drugs, were here identified. Cases were studied and described, including demographic characteristics and clinical data such as concomitant drugs, doses, routes of administration, and outcomes of the reactions (being fatalities recorded). Considering PRR values and in comparison with zopiclone, zolpidem was more frequently involved in both misuse/abuse and withdrawal issues. Zolpidem and zopiclone presented with the same dependence risk, but zopiclone was most involved in overdose adverse drug reactions. Compared with zaleplon, zopiclone presented higher dependence and overdose-related issues but slightly lower misuse/abuse and withdrawal PRR values. CONCLUSION: Current data may only represent a gross underestimate of the real prevalence of Z-drug misuse. Caution should be exercised when prescribing those molecules, especially for patients with psychiatric illnesses and/or history of drug abuse. We recommend the need to invest in proactive pharmacovigilance activities to better and promptly detect, understand, and prevent any possible misuse potential of prescribed medications.
format Online
Article
Text
id pubmed-6441128
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-64411282019-04-04 An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions Schifano, Fabrizio Chiappini, Stefania Corkery, John M Guirguis, Amira Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone (“Z-drugs”) clinical concerns relating to their potential of abuse, dependence, and withdrawal have been reported over time. We aimed here at assessing these issues analyzing datasets of adverse drug reactions provided by the European Medicines Agency through the EudraVigilance system. METHODS: Analyzing the adverse drug reactions databases of each Z-drug, descriptive analyses have been performed on cases and proportional reporting ratios (PRRs) computed. RESULTS: An overall number of 33 240 (e.g., 23 420 zolpidem; 9283 zopiclone; and 537 zaleplon) misuse-, abuse-, dependence-, and withdrawal-related adverse drug reactions, corresponding to some 6246 unique patients given Z-drugs, were here identified. Cases were studied and described, including demographic characteristics and clinical data such as concomitant drugs, doses, routes of administration, and outcomes of the reactions (being fatalities recorded). Considering PRR values and in comparison with zopiclone, zolpidem was more frequently involved in both misuse/abuse and withdrawal issues. Zolpidem and zopiclone presented with the same dependence risk, but zopiclone was most involved in overdose adverse drug reactions. Compared with zaleplon, zopiclone presented higher dependence and overdose-related issues but slightly lower misuse/abuse and withdrawal PRR values. CONCLUSION: Current data may only represent a gross underestimate of the real prevalence of Z-drug misuse. Caution should be exercised when prescribing those molecules, especially for patients with psychiatric illnesses and/or history of drug abuse. We recommend the need to invest in proactive pharmacovigilance activities to better and promptly detect, understand, and prevent any possible misuse potential of prescribed medications. Oxford University Press 2019-02-05 /pmc/articles/PMC6441128/ /pubmed/30722037 http://dx.doi.org/10.1093/ijnp/pyz007 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Regular Research Articles
Schifano, Fabrizio
Chiappini, Stefania
Corkery, John M
Guirguis, Amira
An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
title An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
title_full An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
title_fullStr An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
title_full_unstemmed An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
title_short An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
title_sort insight into z-drug abuse and dependence: an examination of reports to the european medicines agency database of suspected adverse drug reactions
topic Regular Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441128/
https://www.ncbi.nlm.nih.gov/pubmed/30722037
http://dx.doi.org/10.1093/ijnp/pyz007
work_keys_str_mv AT schifanofabrizio aninsightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions
AT chiappinistefania aninsightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions
AT corkeryjohnm aninsightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions
AT guirguisamira aninsightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions
AT schifanofabrizio insightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions
AT chiappinistefania insightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions
AT corkeryjohnm insightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions
AT guirguisamira insightintozdrugabuseanddependenceanexaminationofreportstotheeuropeanmedicinesagencydatabaseofsuspectedadversedrugreactions